DE60315270D1 - Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren - Google Patents

Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren

Info

Publication number
DE60315270D1
DE60315270D1 DE60315270T DE60315270T DE60315270D1 DE 60315270 D1 DE60315270 D1 DE 60315270D1 DE 60315270 T DE60315270 T DE 60315270T DE 60315270 T DE60315270 T DE 60315270T DE 60315270 D1 DE60315270 D1 DE 60315270D1
Authority
DE
Germany
Prior art keywords
inhibitors
gsk
pyrrol
dione derivatives
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315270T
Other languages
English (en)
Other versions
DE60315270T2 (de
Inventor
Pamela Ann Albaugh
Jochen Ammenn
Timothy Paul Burkholder
Joshua Ryan Clayton
Scott Eugene Conner
Brian Eugene Cunningham
Thomas Albert Engler
Kelly Wayne Furness
James Robert Henry
Yihong Li
Sushant Malhotra
Mark Joseph Tebbe
Guoxin Zhu
Brian Raymond Berridge
Charles Edward Ruegg
John Morris Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60315270D1 publication Critical patent/DE60315270D1/de
Publication of DE60315270T2 publication Critical patent/DE60315270T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60315270T 2002-03-08 2003-03-05 Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren Expired - Lifetime DE60315270T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36337502P 2002-03-08 2002-03-08
US363375P 2002-03-08
US36943302P 2002-04-02 2002-04-02
US369433P 2002-04-02
PCT/US2003/005052 WO2003076398A2 (en) 2002-03-08 2003-03-05 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
DE60315270D1 true DE60315270D1 (de) 2007-09-13
DE60315270T2 DE60315270T2 (de) 2008-04-17

Family

ID=27807992

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315270T Expired - Lifetime DE60315270T2 (de) 2002-03-08 2003-03-05 Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren

Country Status (13)

Country Link
US (1) US7405305B2 (de)
EP (1) EP1487822B1 (de)
JP (1) JP2005530707A (de)
KR (1) KR20040091113A (de)
CN (1) CN1639152A (de)
AT (1) ATE368657T1 (de)
AU (1) AU2003217596A1 (de)
CA (1) CA2477984A1 (de)
DE (1) DE60315270T2 (de)
ES (1) ES2289274T3 (de)
IL (1) IL163777A0 (de)
MX (1) MXPA04008671A (de)
WO (1) WO2003076398A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303319D0 (en) * 2003-02-13 2003-03-19 Novartis Ag Organic compounds
KR20060056377A (ko) * 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
EP1885454A2 (de) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Verwendung von gsk-3-hemmern zur prävention und behandlung von pankreatischen autoimmunkrankheiten
PL1904482T3 (pl) * 2005-07-11 2011-06-30 Novartis Ag Pochodne indolilomaleimidowe
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1779851A1 (de) 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Behandlung von Diabetes
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
ES2410955T3 (es) 2006-12-19 2013-07-04 Novartis Ag Derivados de indolilmaleimida como inhibidores de la quinasa
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101812062A (zh) * 2010-03-31 2010-08-25 北京京卫信康医药科技发展有限公司 一种新的米诺膦酸重要中间体的制备方法
CN102443002A (zh) * 2010-10-12 2012-05-09 四川滇虹医药开发有限公司 2-(咪唑并[1，2-α]吡啶-3-基)乙酸的制备方法
CN104906103B (zh) * 2010-12-14 2018-05-18 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
CA2886263C (en) 2012-10-25 2021-04-13 Tetra Discovery Partners, LLC Heteroaryl inhibitors of pde4
US9993463B2 (en) * 2012-12-10 2018-06-12 Centogene Ag Use of maleimide derivatives for preventing and treating cancer
EP2928466B1 (de) * 2012-12-10 2020-10-28 Centogene GmbH Verwendung von maleimidderivaten zur vorbeugung und behandlung von leukämie
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2016049595A1 (en) * 2014-09-26 2016-03-31 Tetra Discovery Partners, LLC Heteroaryl inhibitors of pde4
CN106674079A (zh) * 2015-11-10 2017-05-17 南京卡文迪许生物工程技术有限公司 一种帕比司他的合成方法
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
EP3920885A1 (de) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen
CN113801054A (zh) * 2021-09-30 2021-12-17 西南大学 3-烷基-3-羟基吲哚-2-酮及其衍生物的制备方法及其产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
US6153618A (en) 1996-10-11 2000-11-28 Chiron Corporation Inhibitors of glycogen synthase 3 kinase
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
EP1250334B1 (de) 1999-12-16 2004-05-19 Eli Lilly And Company Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
US6867198B2 (en) 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE284885T1 (de) * 2000-07-27 2005-01-15 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren
AU2737102A (en) 2000-12-08 2002-06-18 Ortho Mcneil Pharm Inc Macroheterocylic compounds useful as kinase inhibitors
KR20040016828A (ko) 2000-12-08 2004-02-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 키나제 저해제로서 인다졸릴-치환된 피롤린 화합물
ATE346070T1 (de) * 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren

Also Published As

Publication number Publication date
MXPA04008671A (es) 2004-12-06
DE60315270T2 (de) 2008-04-17
IL163777A0 (en) 2005-12-18
EP1487822B1 (de) 2007-08-01
KR20040091113A (ko) 2004-10-27
US20050288321A1 (en) 2005-12-29
EP1487822A2 (de) 2004-12-22
CN1639152A (zh) 2005-07-13
JP2005530707A (ja) 2005-10-13
WO2003076398A2 (en) 2003-09-18
WO2003076398A3 (en) 2004-02-26
ES2289274T3 (es) 2008-02-01
AU2003217596A1 (en) 2003-09-22
US7405305B2 (en) 2008-07-29
CA2477984A1 (en) 2003-09-18
ATE368657T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DE60315270D1 (de) Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
DK1761520T3 (da) Kinaseinhibitorer
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
ATE512151T1 (de) Pyrrolotriazin-kinaseinhibitoren
UA85505C2 (en) Kinase inhibitors
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DE60304360D1 (de) N-aryl-2-oxazolidinone und deren derivate
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
ITMI20022739A1 (it) Derivati ftalazinici inibitori della fosfodiesterasi 4.
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN